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BACKGROUND: Black patients are at greater of risk of death from bladder cancer than white patients. Potential
explanations for this disparity include a more aggressive phenotype and delays in diagnosis resulting in higher stage
disease. Alternatively, black patients may receive a lower quality of care, which may explain this difference. METH-
ODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data for the years from 1992 through
2002, the authors identified patients with early stage bladder cancer. Multivariate models were fitted to measure rela-
tions between race and mortality, adjusting for differences in patients and treatment intensity. Next, shared-frailty
proportional hazards models were fitted to evaluate whether the disparity was explained by differences in the quality
of care provided. RESULTS: Compared with white patients (n ¼ 14,271), black patients (n ¼ 342) were more likely to
undergo restaging resection (12% vs 6.5%; P < .01) and urine cytologic evaluation (36.8% vs 29.7%; P < .01), yet they
received fewer endoscopic evaluations (4 vs 5; P < .01). The use of aggressive therapies (cystectomy, systemic chem-
otherapy, radiation) was found to be similar among black patients and white patients (12% vs 10.2%, respectively; P ¼
.31). Although black patients had a greater risk of death compared with white patients (hazards ratio [HR], 1.23; 95%
confidence interval [95% CI], 1.07-1.42), this risk was attenuated only modestly after adjusting for differences in treat-
ment intensity and provider effects (HR, 1.22; 95% CI, 1.06-1.42). CONCLUSIONS: Although differences in initial treat-
ment were evident, they did not appear to be systematic and had unclear clinical significance.Whereas black patients
are at greater risk of death, this disparity did not appear to be caused by differences in the intensity or quality of care
provided.Cancer 2010;116:50–6.VC 2010 American Cancer Society.
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Among those with bladder cancer, black patients have an approximately 70% greater risk of cancer-related death
compared with white patients.1 Even among those with localized disease, black patients have significantly worse 10-year
disease-specific survival (81% vs 88%).2 Although the underpinnings for this disparity are not entirely clear, plausible
explanations include a more aggressive cancer phenotype (ie, tumor biology), delays in diagnosis that result in higher stage
disease at presentation, and a greater burden of comorbid diseases. Since early stage (ie, superficial or nonmuscle-invasive)
bladder cancer traditionally is considered a nonlethal disease, comorbidity may be an important contributor to apparent
cancer-related mortality because of difficulties in ascertaining the cause of death (ie, attribution bias).3
Alternatively, disparities in survival may be the end result of differences in the healthcare provided to black patients
and white patients. On one hand, the disparity may reflect differential treatment by race. Among those with early stage
lung cancer, the lower survival rate for black patients appears to be because patients in this group less frequently undergo
surgery.4 With regard to early stage bladder cancer, differences in the use of surveillance (eg, endoscopy) and treatment
(eg, intravesical therapy) may underlie the observed survival disparity. Conversely, survival differences may be attributable
to the quality of care provided. Black patients who undergo radical cystectomy are nearly 70%more likely to die postoper-
atively compared with white patients,5 a finding that is largely a consequence of the quality of the hospital setting6 in
which black patients more commonly receive their care (ie, low volume with limited access to potentially necessary health
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services). In the setting of early stage bladder cancer, the
physician, rather than the hospital, plays a principal role
in determining treatment and outcomes. Because black
patients and white patients generally receive their care by
dissimilar physicians,7 differences in the quality of the
bladder cancer care provided may explain the observed
disparity in mortality.
For this reason, we undertook a study to better
understand racial differences in the treatment of patients
with early stage bladder cancer. Using national Surveil-
lance, Epidemiology, and End Results (SEER)-Medicare
data, we explored the extent to which disparities in mor-
tality are explained by differences in the intensity and
quality of the care provided.
MATERIALS AND METHODS
Study Population
We used the SEER-Medicare linked database for the years
1992 through 2002 to identify patients who were diag-
nosed with early stage bladder cancer. These files provide
information on Medicare patients who are included in
SEER,8 a collection of population-based registries of all
incident cancers that comprised approximately 26% of
the United States population by the end of the study pe-
riod.9 For each Medicare patient in SEER, the SEER-
Medicare linked files contain 100% of Medicare claims
from the inpatient, outpatient, and national claims history
files.
From these files, all fee-for-service Medicare patients
ages 65 years to 99 years with incident cases of bladder
cancer were identified by the appropriate code in SEER.
We limited our study population to patients with early
stage bladder cancer (noninvasive papillary carcinoma
[Ta], carcinoma in situ [Tis], and tumor invading subepi-
thelial connective tissue [T1])10 using the extent-of-dis-
ease codes provided by SEER. All patients were followed
usingMedicare claims through December 31, 2005.
Characterization of Treatment
We explored how patients with bladder cancer were
managed using International Classification of Diseases,Ninth
Revision (ICD-9) procedure and Healthcare Common Pro-
cedure Coding System (HCPCS) codes recorded in the
Medicare files during the first 2 years after diagnosis. We
focused on practices that were relevant to early stage bladder
cancer care, including surveillance (endoscopic examination
of the bladder, upper urinary tract evaluation, urinary stud-
ies, and imaging studies), treatment (intravesical therapy
and repeat endoscopic resection within 60 days of the initial
resection), and medical services (visits to the urologist and
visits to other physicians).
To serve as a proxy for initial treatment intensity, we
used early stage bladder cancer expenditures within the
first 2 years after diagnosis. Briefly, expenditures were
measured at the patient level and included all Medicare
payments associated with a primary diagnosis of bladder
cancer (ICD-9 codes: 188.x, bladder cancer; 233.7, carci-
noma in situ of the bladder; and V105.4, personal history
of bladder cancer). Expenditures related to major inter-
ventions (cystectomy, chemotherapy, and radiotherapy)
were not included. All payments were price-adjusted to
2005 US dollars using the Medicare Economic Index and
were standardized by region.11
Because an objective of our study was to evaluate the
extent to which any observed disparity in mortality was
attributable to the quality of care provided by the treating
physician, it was necessary to assign each patient to a pro-
vider. To ascertain the physician who was primarily re-
sponsible for each patient’s bladder cancer care, we first
identified all bladder cancer-related procedures, as
described by others,12 that were performed within a 2-
year period after their diagnosis. Next, we allocated each
patient to the provider with the majority of claims using
the Unique Physician Identifier Number. Because it was
necessary to obtain reliable estimates of physician’s prac-
tice styles, we limited our study only to those physicians
who had 10 patients. Using this method, our final pop-
ulation was comprised of 14,613 patients who were
treated by 656 providers.
Outcomes
Our primary outcome measure was mortality, which
was assessed from January 1, 1992 through December 31,
2005. Because of concerns regarding appropriately assign-
ing the cause of death,3,13-16 we used all-cause mortality as
our primary outcome. However, recognizing that the vast
majority of patients with early stage bladder cancer are
likely to die from competing causes,17 we also measured
bladder cancer-specific mortality using the cause-of-death
field available in SEER. We also assessed the use of a
major intervention, as evidenced by the use of radical
cystectomy, systemic chemotherapy, and radiotherapy,
which could occur at any time during the study period.
Furthermore, a composite variable was constructed to
reflect the downstream use of any of these therapies. These
secondary outcomes were identified by using appropriate
ICD-9 and HCPCS codes in the inpatient, national
claims history, and outpatient files.
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Statistical Analysis
For all of our analyses, our exposure was patient-level race
(white, black) as measured by SEER. First, we examined
differences in patient demographics and disease character-
istics according to race. Then, we characterized the extent
to which early stage bladder cancer care (surveillance,
treatment, and medical services) varied by race. For all of
these comparisons, statistical inference was made using
chi-square or Kruskal-Wallis tests for categoric and con-
tinuous data, respectively.
For the purpose of understanding the correlation
between race and mortality, we fitted Cox proportional
hazards models that were adjusted for patient and disease
characteristics, including patient age group (5-year inter-
vals), sex, tumor grade (low, medium, high, and
unknown), and tumor stage (Ta, Tis, T1, and Ta/T1
unspecified).10 In addition, we adjusted for socioeco-
nomic status using a composite measure assessed at the
ZIP code level, as described by Diez-Roux et al.18 Patient
comorbidities were identified by using healthcare encoun-
ters in the 12-month period preceding the bladder cancer
diagnosis according to the well established methods
described by Klabunde et al.19 Next, we evaluated the
extent to which variation in the intensity of initial treat-
ment for bladder cancer provided might explain differen-
ces in mortality by adjusting for patient-level treatment
intensity. Finally, we explored whether the provider con-
tributed to any observed disparities in survival by fitting a
shared-frailty proportional hazards model, including a
provider-level, random-effects term.20 This approach
accounts for the correlation of mortality outcomes within
a provider and for the heterogeneity between providers.
For the secondary outcomes (use of cystectomy, sys-
temic chemotherapy, and/or radiotherapy), we fitted gen-
eralized estimating equations to evaluate the correlation
between race and each patient-level outcome, adjusting
for age, sex, comorbidity, socioeconomic status, tumor
grade, and tumor stage. This approach allowed us to
account for the potential correlation of our observations
(ie, patients clustered within providers).21 We then used
postestimation commands to predict adjusted percentages
for the receipt of each intervention by race.
All analyses were performed using computerized
software (SAS version 9.2 [SAS Inc, Cary, NC] Stata [ver-
sion 10; Stata Corp., College Station, Tex]). All tests were
2-tailed, and the probability of Type 1 error was set at .05.
The study protocol was approved by the Institutional
Review Board of the University of Michigan.
RESULTS
Black patients with early stage bladder cancer had a signif-
icantly lower median overall survival rate compared with
white patients (4.4 years vs 6.5 years; log-rank P < .001).
Table 1 illustrates differences in patient and disease char-
acteristics according to race. It is interesting to note that
black patients had lower socioeconomic status and higher
levels of comorbidity (P< .01 for both). However, disease
severity at diagnosis, as measured by cancer grade and
stage, did not vary by race.
The initial treatment of early stage bladder cancer
care varied according to race (Table 2). Generally, black
patients were followed more intensively with urine cytol-
ogy (0.80 tests vs 0.71 tests; P < .01). Moreover, black
patients were nearly twice as likely to undergo restaging
resection of their cancer compared with white patients
(12% vs 6.5%; P < .01). In contrast, black patients had
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AJCC indicates American Joint Committee on Cancer; Tis, tumor in situ.
* Represents expenditures median per capita expenditures for the first 2
years after diagnosis.
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fewer endoscopic bladder cancer evaluations compared
with white patients (4 studies vs 5 studies; P < .01). The
use of intravesical therapy did not vary by race.
The overall use of downstream major interventions
was similar among black patients and white patients (Fig.
1). Although black patients were more likely to receive
radiotherapy (5.6% vs 3.2%; P¼ .02) and systemic chem-
otherapy (8.1% vs 5.3%; P ¼ .04) compared with white
patients, the use of radical cystectomy was similar between
the 2 groups. On average, the use of any major interven-
tion did not vary significantly by race, and 12% of black
patients and 10.2% of white patients received treatment
(P¼ .31).
Black patients had a 23% greater risk of death com-
pared with white patients after adjusting for differences in
clinical characteristics, as illustrated in Table 3. This risk
was attenuated only modestly after adjusting for differen-
ces in treatment intensity and the effect of the provider
(adjusted hazards ratio, 1.22; 95% confidence interval,
1.06-1.42). Similar modest attenuations were evident
within stage strata and when using cancer-specific survival
as the outcome.
DISCUSSION
Black patients who are diagnosed with early stage bladder
cancer are at greater risk of death compared with white
patients. However, this disparity did not appear to be caused
by presentation with more severe disease, as measured by
bladder cancer stage and grade. Not surprisingly, early stage
bladder cancer care varied by race, although the majority of
these differences had questionable clinical significance. Lack-
ing context, these findings may suggest gaps in the quality
of care as a principal source for this disparity. However,
differences in initial treatment intensity and in the provider
responsible for the bladder cancer care failed to account for
virtually any of the excess mortality risk. Furthermore, the
use of major medical interventions, including radical cystec-
tomy, was similar among black and white patients.
Racial disparities in survival after a cancer diagnosis
have been well described for a variety of malignancies,
including bladder cancer.2,5,6 In 1 study, black patients
had a nearly 70% greater risk of dying from bladder can-
cer compared with white patients.1 However, investiga-
tions into the underpinnings of this disparity largely have
focused on delayed diagnosis2 or perioperative care after
radical cystectomy, which traditionally has had higher op-
erative mortality rates for blacks.5,6 In 1 study that used
national data, black patients were 66% more likely to die
Table 2. Differences in Early Stage Bladder Cancer Care
During the First 2 Years After Diagnosis
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Any urine cytology, %y 29.7 36.8 .006


















Visits to the other
physicians, mean*
21.7 25.5 <.001
* For continuous measures (eg, endoscopic surveillance), the mean repre-
sents the average number of the services performed for each patient. For
example, on average, black patients underwent 4 endoscopic procedures,
and white patients underwent 5 endoscopic procedures during the first 2
years after diagnosis.
yFor categoric measures (eg, any upper tract evaluation), the percentage
represents the fraction of patients receiving that service. For example,
25.7% of black patients and 24.9% of white patients had any upper tract
imaging performed within the first 2 years after diagnosis.
zAn induction course represents at least 5 instillations within a 45-day
period.
Figure 1. These charts illustrate the use of major interventions
stratified by race and adjusted for age, sex, socioeconomic
status, comorbidity, cancer grade, and cancer stage.
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perioperatively compared with white patients, even after
adjusting for patient differences.5 For such high-risk pro-
cedures, it is believed generally that these disparities are a
direct reflection of hospital quality and the finding that
minorities generally seek care at lower quality hospitals.22
In fact, white patients and black patients tend to have sim-
ilar mortality rates when they are treated at the same hos-
pital,6 underscoring the importance of the setting and the
provider to high-risk operations.
It is interesting to note that the current study illus-
trates that racial disparities in mortality are equally evident
for those with early stage bladder cancer. Among patients
who are diagnosed with bladder cancers in all stages, black
patients are diagnosed with more advanced disease,23 a dis-
crepancy that generally has been thought to underlie the
observed survival differences. However, in the current
study of patients with early stage disease, we did not
observe a predilection for more aggressive phenotypes (eg,
T1 bladder cancer) by race. That is, racial differences in
survival in this population were not secondary to higher
grade and higher stage bladder cancer. Furthermore, in
contrast to the literature surrounding radical cystectomy,
we observed no protective effect of the provider on survival
differences. Indeed, our data indicate that the mortality dis-
parity is persistent and equally robust even after adjusting
for differences in the provider and the treatment intensity.
A principal limitation of our analysis relates to
unmeasured patient differences that may confound corre-
lations between race and mortality, an important consid-
eration given the relatively small number of black patients
in the study. In particular, black patients may have more
aggressive bladder cancer and medical diseases that
explain disparities in mortality risk. We addressed this
well described limitation of observational data24,25 in









White patients 1.0 1.0 1.0
Black patients 1.23 (1.07-1.42) 1.22 (1.06-1.42) 1.22 (1.06-1.42)
By AJCC tumor stage
Ta
White patients 1.0 1.0 1.0
Black patients 1.33 (1.08-1.63) 1.34 (1.09-1.66) 1.35 (1.09-1.66)
T1
White patients 1.0 1.0 1.0
Black patients 1.41 (1.10-1.83) 1.40 (1.09-1.81) 1.40 (1.08-1.81)
Tis
White patients 1.0 1.0 1.0
Black patients 1.03 (0.64-1.65) 1.04 (0.65-1.66) 1.05 (0.62-1.76)
Cancer-specific mortality
All patients
White patients 1.0 1.0 1.0
Black patients 1.79 (1.30-2.47) 1.85 (1.35-2.56) 1.73 (1.23-2.43)
By AJCC tumor stage
Ta
White patients 1.0 1.0 1.0
Black patients 2.28 (1.34-3.87) 2.37 (1.40-4.02) 2.34 (1.33-4.10)
T1
White patients 1.0 1.0 1.0
Black patients 1.79 (1.11-2.88) 1.83 (1.14-2.95) 1.86 (1.12-3.09)
Tis
White patients 1.0 1.0 1.0
Black patients 2.16 (0.75-6.20) 2.21 (0.76-6.41) 2.24 (0.72-6.99)
HR indicates hazards ratio; 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; Tis, tumor in
situ.
* Adjusted for age, sex, socioeconomic status, comorbidity, grade, and tumor stage (note, for stage strata models, stage
was not included as a covariate).
yAdjusted for the above-mentioned variables and patient-level treatment intensity.
zAdjusted for the above-mentioned variables and provider as a random effect.
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several ways. First, we used a clinical registry to ascertain
cancer stage and grade, which, arguably, are the most im-
portant determinants of death in the bladder cancer popu-
lation.26,27 Second, we ascertained comorbid conditions
using a well described methodology19 that incorporated
data from both inpatient and outpatient claims. Because
of entitlement issues, our comorbidity assessment (using
12 months of data before diagnosis) may underestimate
the disease burden among patients aged 65 years, who
would have more limited claims information. However,
these patients had a median entitlement period of approx-
imately 8 months (range, 45-365 days), so the effects of
such underestimation most likely are limited. Further-
more, although more detailed measures of patients’ health
status may improve our ability to adjust according to risk,
this would require a large, detailed clinical registry, which
is not possible for practical reasons (eg, cost, sample size).
Although we accounted for additional demographic dif-
ferences using a composite measure for socioeconomic
status,18 which is a well described predictor of long-term
mortality,28 we recognize that race and class are complex
constructs that cannot always be captured comprehen-
sively in administrative data.
As with any observational study, there are additional
limitations to consider. Because we used national SEER-
Medicare data, our findings may not be generalizable to
patients aged<65 years. However, because nearly 75% of
bladder cancers occur within the Medicare population,9
the extrapolation of our findings to a broader cohort
appears to be reasonable. Finally, we acknowledge that
race, as captured in SEER data, represents a constellation
of constructs as described by others,29 including accultur-
ation, education, socioeconomic class, and socialization.
Future work should seek to disentangle this complicated
web and evaluate these relations in other minority
populations.
Compared with white patients who have early stage
bladder cancer, black patients are at significantly greater
risk of death. This disparity is not attributable to the diag-
nosis with more aggressive disease, the initial treatment
intensity, or the quality of care provided by the urologist.
Eliminating disparities in mortality for this chronic dis-
ease likely will require searching looking beyond the fac-
tors that pertain to healthcare delivery alone. Such factors,
including behavior modification (eg, smoking cessation)
and greater use of other preventive services, inevitably
may lie upstream from the diagnosis of bladder cancer,
imparting significant, but not insurmountable, challenges
for future research.
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